title: Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
authors.affiliation: Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Matheus F
authors.initials: MF
authors.lastname: Bezerra
authors.affiliation: Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Juan L
authors.initials: JL
authors.lastname: Coelho-Silva
authors.affiliation: Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Nascimento
authors.affiliation: Department of Internal Medicine, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil.
authors.forename: Mariana T
authors.initials: MT
authors.lastname: Benicio
authors.affiliation: Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Cintia R
authors.initials: CR
authors.lastname: Rocha
authors.affiliation: Department of Internal Medicine, Hematology and Hemotherapy Foundation of Pernambuco, Recife, Brazil.
authors.forename: Cintia G
authors.initials: CG
authors.lastname: Machado
authors.affiliation: Department of Internal Medicine, Medical School of Ribeirao Preto, Ribeirao Preto, Brazil.
authors.forename: Eduardo M
authors.initials: EM
authors.lastname: Rego
authors.affiliation: Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Marcos A
authors.initials: MA
authors.lastname: Bezerra
authors.affiliation: Department of Genetics, Federal University of Pernambuco, Recife, Brazil araujoarl@hotmail.com.
authors.forename: Antonio R
authors.initials: AR
authors.lastname: Lucena-Araujo
authors.affiliation: Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Recife, Brazil.|Department of Biochemistry, Federal University of Pernambuco, Recife, Brazil.
authors.forename: Eduardo I
authors.initials: EI
authors.lastname: Beltrão
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression; D020022:Genetic Predisposition to Disease; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D013866:Thioguanine / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D003561:Cytarabine; D005047:Etoposide; D013866:Thioguanine; D015255:Idarubicin; D003630:Daunorubicin